摘要
新型冠状病毒(以下简称新冠)感染是一类世界流行的传染性疾病。炎症性肠病(IBD)患者常应用免疫抑制相关药物,该类患者的新冠疫苗接种及感染新冠时治疗药物的管理对临床医师具有很大挑战。现针对2020年中华医学会消化病学分会炎症性肠病学组关于《炎症性肠病患者在新型冠状病毒肺炎流行期间的管理》进行补充修订,主要内容包括IBD患者合并新冠感染时治疗药物的管理,以及IBD患者新冠疫苗接种的相关事宜,期望能指导临床医师合理用药,并指导IBD患者在合适的时机进行疫苗接种,帮助患者安全而平稳地度过新冠流行时期。
Coronavirus disease 2019(COVID-19)has become a worldwide pandemic.During the rapid spread time,it is a great challenge for patients with inflammatory bowel disease(IBD)who use immunosuppressive drugs from vaccination and drug application.This article is intended to supplement and revise the recommendations of the Inflammatory Bowel Disease Group of the Chinese Society of Gastroenterology in 2020 on the"Management of patients with inflammatory bowel disease during epidemic of novel coronavirus pneumonia",mainly including the treatment and vaccination of IBD patients complicated with COVID-19.It is expected to guide clinicians in drug use,vaccination of IBD patients at an appropriate time,also help patients getting through the epidemic period of COVID-19.
作者
杨红
朱良如
梁洁
钱家鸣
吴开春
中华医学会消化病学分会炎症性肠病学组
Yang Hong;Zhu Liangru;Liang Jie;Qian Jiaming;Wu Kaichun;Inflammatory Bowel Disease Group,Chinese Society of Gastroenterology,Chinese Medical Association(Department of Gastroenterology,Peking Union Medical College Hospital,Chinese Academy of Medical Science&Peking Union Medical College,Beijing 100730,China;Department of Gastroenterology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China;Department of Gastroenterology,the First Affiliated Hospital of Air Force Medical University,Xi′an 710032,China;不详)
出处
《中华消化杂志》
CAS
CSCD
北大核心
2023年第2期84-88,共5页
Chinese Journal of Digestion
关键词
冠状病毒感染
炎症性肠病
药物
疫苗
管理
Coronavirus infections
Inflammatory bowel diseases
Drugs
Vaccine
Management
